Skip to main content

Market Overview

Morning Market Movers

Share:

Cubist Pharmaceuticals (NASDAQ: CBST) shares climbed 35.66% to $100.88 after Merck (NYSE: MRK) announced its plans to acquire Cubist for $102 per share in cash.

BioLineRx (NASDAQ: BLRX) shares jumped 17.47% to $1.74 after the company reported positive data from ongoing Phase 2a Study for AML treatment.

Louisiana-Pacific (NYSE: LPX) shares gained 9.85% to $17.03. Louisiana-Pacific shares have dropped 3.85% over the past 52 weeks, while the S&P 500 index has gained 14.76% in the same period.

Acceleron Pharma (NASDAQ: XLRN) rose 7.56% to $40.40. Celgene (NASDAQ: CELG) and Acceleron announced new data from Luspatercept Phase 2 clinical trial in beta-thalassemia.

Agios Pharmaceuticals (NASDAQ: AGIO) shares surged 3.42% to $109.65 after the company reported Celgene decision to extend discovery phase of global strategic collaboration to April 2016. The company also announced positive data from ongoing Phase 1 trial of AG-221 at ASH Annual Meeting.

Randgold Resources (NASDAQ: GOLD) shares jumped 2.76% to $66.64 after falling 2.26% on Friday.

Celgene (NASDAQ: CELG) shares climbed 2.42% to $116.89 after the company and Acceleron Pharma (NASDAQ: XLRN) announced new data from
Luspatercept Phase 2 clinical trial in beta-thalassemia.

The Nasdaq OMX Group (NASDAQ: NDAQ) rose 1.53% to $46.38 after analysts at Keefe Bruyette & Woods upgraded the stock from Market Perform to Outperform and raised the price target from $45 to $55.

 

Related Articles (CBST + MRK)

View Comments and Join the Discussion!

Posted-In: market moversNews Intraday Update Markets Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com